Ranunculin, a glucoside, serves as a chemotaxonomic marker in Ranunculaceae
plants. When these plants are damaged, an enzyme β−glucosidase triggers the
conversion of ranunculin into protoanemonin through hydrolysis. Subsequently, protoanemonin
undergoes cyclodimerization to form anemonin. The inherent instability of
ranunculin and the rapid dimerization of protoanemonin render them unsuitable for use
in biological assays. Conversely, anemonin stands out as the optimal molecule for bioassays
and demonstrates diverse biological properties, including anti-inflammatory, anti-infective,
and anti-oxidant effects. Among these, anemonin exhibits the greatest promise
in addressing arthritis, cerebral ischemia, and ulcerative colitis. Its potential medical uses
are enhanced by its capacity to inhibit nitric oxide synthesis and successfully counteract
lipopolysaccharide-induced inflammation. This review describes the chemistry and
biological properties of anemonin and its precursors, including discussions on extraction,
isolation, synthesis, and investigations into bioactivity and pharmacokinetics.